Vandetanib: Difference between revisions
m Protected "Vandetanib": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
| Line 25: | Line 25: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
| Line 41: | Line 41: | ||
{{Chemotherapeutic agents}} | {{Chemotherapeutic agents}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 17:18, 20 August 2012
| File:Vandetanib.svg | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Elimination half-life | 5 days (mean) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C22H24BrFN4O2 |
| Molar mass | 475.354 g/mol |
|
WikiDoc Resources for Vandetanib |
|
Articles |
|---|
|
Most recent articles on Vandetanib |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Vandetanib at Clinical Trials.gov Clinical Trials on Vandetanib at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Vandetanib
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Vandetanib Discussion groups on Vandetanib Patient Handouts on Vandetanib Directions to Hospitals Treating Vandetanib Risk calculators and risk factors for Vandetanib
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Vandetanib |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Vandetanib (rINN, trade name Zactima), also known as ZD6474, is a medication currently undergoing clinical trials as a potential targeted treatment for non–small-cell lung cancer. It is an antagonist of the vascular endothelial growth factor receptor (VEGFR) and the epidermal growth factor receptor (EGFR).
Vandetanib is being developed by AstraZeneca.
External links
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Angiogenesis inhibitors
- Tyrosine kinase inhibitors